ArticleMolecular cancer research : MCR2018
Characterization and Evidence of the miR-888 Cluster as a Novel Cancer Network in Prostate.
Article in Molecular cancer research : MCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Molecular Cargo of Exosomes in Prostate Cancer: A Multi-Omics Perspective on Liquid Biopsies.Genes · 2025Review
- Systematic characterization of cross-source miRNA biomarkers in prostate cancer with computational-experimental integrated analysis.Frontiers in cell and developmental biology · 2025Article
- The role and mechanisms of exosome microRNA in regulating metastasis within the tumor microenvironment of prostate cancer.Frontiers in oncology · 2025Review
- Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers.Non-coding RNA research · 2024Review
- Exploring the Therapeutic Potential ofInternational journal of molecular sciences · 2023Article
- Urinary extracellular vesicles miRNA-A new era of prostate cancer biomarkers.Frontiers in genetics · 2023Review
- Small regulatory RNAs: from bench to bedside - a keystone symposia meeting report.RNA biology · 2023Article
- TENT2, TUT4, and TUT7 selectively regulate miRNA sequence and abundance.Nature communications · 2022Article
- Article
- Small extracellular vesicles as a multicomponent biomarker platform in urinary tract carcinomas.Frontiers in molecular biosciences · 2022Review
- Exosomal lncAY927529 enhances prostate cancer cell proliferation and invasion through regulating bone microenvironment.Cell cycle (Georgetown, Tex.) · 2021Article
- CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis.Prostate cancer and prostatic diseases · 2021Article
- Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis.Cancer medicine · 2021Article
- ChrXq27.3 miRNA cluster functions in cancer development.Journal of experimental & clinical cancer research : CR · 2021Review
- Emerging Role of Exosomes in Liquid Biopsy for Monitoring Prostate Cancer Invasion and Metastasis.Frontiers in cell and developmental biology · 2021Review
- Pan-cancer analysis of somatic mutations in miRNA genes.EBioMedicine · 2020Article
- Article
- Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Prostate cancer afflicts 1 in 7 men and is the second leading cause of male cancer-related deaths in the United States. MicroRNAs (miRNAs), an extensive class of approximately 22 nucleotide noncoding RNAs, are often aberrantly expressed in tissues and fluids from prostate cancer patients, but the mechanisms of how specific miRNAs regulate prostate tumorigenesis and metastasis are poorly understood. Here, miR-888 was identified as a novel prostate factor that promotes proliferation and migration. miR-888 resides within a genomic cluster of 7 miRNA genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.